Oak Ridge, TN, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will attend the H.C. Wainwright 24th Annual Global Investment Conference being held on September 12 – 14, 2022 at the Lotte New York Palace.
→ Google ترجمة
Daxor Corporation (NASDAQ:NASDAQ:DXR) Q2 2022 Earnings Conference Call August 25, 2022, 04:30 PM ET Company Participants Scott Gordon - President and Co-Founder of CORE IR Michael Feldschuh…
→ Google ترجمة
Daxor press release (DXR): Q2 The increase in revenue of 92.6 percent in the Company’s operating division represents strong strides in the commercialization of its BVA-100.As of June…
→ Google ترجمة
Daxor press release (DXR): FY NAV of $5.24 per share versus $3.89 in FY 2020.
→ Google ترجمة
Daxor ’s BVA-100 ® Shown to Provide Unique and Actionable Data for Addressing Heart Failure
→ Google ترجمة
NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has signed a non-government distribution agreement with Concordance Healthcare Solutions, one of the largest independent healthcare distributors in the U.S. Daxor and Concordance will work together to provide Daxors BVA-100 ® (Blood Volume Analyzer) diagnostic blood test to healthcare facilities nationally, driving the use of blood volume measurement to help guide precise, individualized volume management in a wide variety of medical conditions including heart failure and critical care.
→ Google ترجمة
Cites Evidence from Studies Utilizing Daxors BVA-100 ® Blood Volume Analyzer
→ Google ترجمة
Daxor Corporation (DXR) shares closed this week 40.6% higher than it did at the end of last week. The stock is currently up 5.2% year-to-date, down 9.1% over the past 12 months, and up 67.4% over the past five years. This week, the Dow Jones Industrial Average rose 0.7%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $13.46 and as low as $9.16 this week.Shares closed 4e+1% below its 52-week high and 6e+1% above its 52-week low.Trading volume this week was 275.6% higher than the 10-day average and 666.4% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -54.2% The company's stock price performance over the past 12 months lags the peer average by -127.0%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
→ Google ترجمة
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that Michael Feldschuh, Daxors President and Chief Executive Officer will present at the Summer Solstice - Best Ideas from the Buy Side Conference, which is being held virtually on June 2, 2021 at 4:30 PM ET.
→ Google ترجمة
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Daxor (DXR), CareDx (CDNA) and Allogene The post Analysts Offer Insights on Healthcare Companies: Daxor (DXR), CareDx (CDNA) and Allogene Therapeutics (ALLO) appeared first on Smarter Analyst .
→ Google ترجمة
NEW YORK, NY, May 13, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announced a Q1 2021 increase in revenue of 61% in its operating division on a year-over-year basis. In addition, the sales team has recorded the opening of five new customer accounts utilizing BVA and reports a growing pipeline of additional acquisitions
→ Google ترجمة
Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announced a Q1 2021 increase in revenue of 61% in its operating division on a year-over-year basis. In addition, the sales team has recorded the opening of five new customer accounts utilizing BVA and reports a growing pipeline of additional acquisitions of Daxors BVA-100 Blood Volume Analyzer slated for Q3 2021
→ Google ترجمة
Daxor Corporation (NYSE: DXR ) President and CEO Michael Feldschuh participated in the Benzinga Biotech Small Cap Conference held on March 24, 2021. He provided an overview on Daxor’s business model and growth strategy, including updates on groundbreaking research and product development as well as new prospective medical trials. Daxor Corporation continues to make news with its breakthrough technology focusing on blood volume measurement innovation. The company developed and markets the BVA-100® (blood volume analyzer), the first and only diagnostic blood test cleared by the Food and Drug Administration (FDA). It provides safe, accurate and objective quantifications of blood volume status and composition compared to patient-specific norms for a variety of medical and surgical conditions including heart failure and critical care. The BVA test is administered at the point of care and samples are sent to the lab to be processed. Within 1 hour or less, results are generated. Over 50,000 blood tests have been performed at leading hospitals across the country since its introduction and has been shown to reduce heart failure mortality by over 80% and readmissions by over 56% in peer-reviewed studies confirming that accurate blood volume measurement enhances hospital performance metrics and leads to better patient outcomes.
→ Google ترجمة
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology (organized as an…
→ Google ترجمة
NEW YORK, August 4, 2020 - Daxor Corporation , an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced… | August 4, 2020
→ Google ترجمة
Daxor Corporation (DXR -13.8%) agrees to issue 125K common shares and 225K shares from the Estate of Joseph Feldschuh at $20/share, for gross proceeds of $
→ Google ترجمة
NEW YORK, July 20, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE American: DXR) (“Daxor” or the “Company”), an investment company with innovative…
→ Google ترجمة
In yet another example of the animal spirits related to any company that even mentions coronavirus, ultra-thinly traded nano cap Daxor (NYSEMKT:DXR) is up
→ Google ترجمة
NEW YORK, May 31, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR ), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Michael Feldschuh, chief executive officer of Daxor Corporation, will be a featured presenter at the LD Micro Invitational Conference on Tuesday, June 4 th at 9:40 AM Pacific Time. The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Mr. Feldschuh will provide an overview of the company's business model and growth strategy, and will be available for one-on-one meetings. Interested investors may request a meeting time by contacting Bret Shapiro at COREIR either by calling 1-561-479-8566 or emailing brets@coreir.com . About Daxor Corporation Daxor Corporation is an innovative medical instrumentation and biotechnology company. … Full story available on Benzinga.com
→ Google ترجمة
What games you'll be able to play with ray-tracing tech (also known as DXR) on NVIDIA GTX cards depends entirely on how it's implemented.
→ Google ترجمة